These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 20560996)

  • 1. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
    Seeman P
    CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
    Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
    Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosis pathways converge via D2high dopamine receptors.
    Seeman P; Schwarz J; Chen JF; Szechtman H; Perreault M; McKnight GS; Roder JC; Quirion R; Boksa P; Srivastava LK; Yanai K; Weinshenker D; Sumiyoshi T
    Synapse; 2006 Sep; 60(4):319-46. PubMed ID: 16786561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia and dopamine receptors.
    Seeman P
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):999-1009. PubMed ID: 23860356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is schizophrenia a dopamine supersensitivity psychotic reaction?
    Seeman MV; Seeman P
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():155-60. PubMed ID: 24128684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic-evoked dopamine supersensitivity.
    Servonnet A; Samaha AN
    Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Seeman P; Tallerico T
    Mol Psychiatry; 1998 Mar; 3(2):123-34. PubMed ID: 9577836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
    Nakata Y; Kanahara N; Iyo M
    J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the dopamine D2 receptor in schizophrenia.
    Seeman P
    Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
    Kanahara N; Kimura H; Oda Y; Ito F; Iyo M
    Curr Neuropharmacol; 2021; 19(12):2214-2226. PubMed ID: 33550976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
    Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
    J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
    Oda Y; Kanahara N; Iyo M
    Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.
    Samaha AN; Seeman P; Stewart J; Rajabi H; Kapur S
    J Neurosci; 2007 Mar; 27(11):2979-86. PubMed ID: 17360921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are dopamine D2 receptors out of control in psychosis?
    Seeman P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():146-52. PubMed ID: 23880595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic-induced supersensitivity - A reappraisal.
    Lugg W
    Aust N Z J Psychiatry; 2022 May; 56(5):437-444. PubMed ID: 34144649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
    Seeman P; Tallerico T
    Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
    Takase M; Kimura H; Kanahara N; Nakata Y; Iyo M
    J Psychopharmacol; 2020 May; 34(5):540-547. PubMed ID: 31961236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
    Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
    J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.